Zanocin OZ Tablet is a combination antibiotic formulation containing Ofloxacin 200 mg and Ornidazole 500 mg, designed for the treatment of mixed bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, exerts its bactericidal action by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription in susceptible organisms. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by causing DNA strand breakage and inhibiting nucleic acid synthesis. This dual-action tablet is commonly prescribed for infections involving both aerobic and anaerobic pathogens, such as gastrointestinal infections, genitourinary tract infections, intra-abdominal infections, and certain sexually transmitted diseases. Zanocin OZ is particularly useful in treating conditions like bacterial dysentery, amoebiasis, trichomoniasis, and mixed aerobic-anaerobic infections where monotherapy may be insufficient. The combination enhances therapeutic efficacy and reduces the risk of resistance development. Dosage and duration of therapy should be determined by a healthcare professional based on the severity and type of infection. Patients should use Zanocin OZ with caution if they have a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and it is contraindicated during pregnancy and lactation. Adverse effects may include gastrointestinal disturbances, dizziness, and hypersensitivity reactions.